Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.
Boziki M, Bakirtzis C, Sintila SA, Kesidou E, Gounari E, Ioakimidou A, Tsavdaridou V, Skoura L, Fylaktou A, Nikolaidou V, Stangou M, Nikolaidis I, Giantzi V, Karafoulidou E, Theotokis P, Grigoriadis N.
Boziki M, et al. Among authors: stangou m.
Cells. 2022 Jun 17;11(12):1959. doi: 10.3390/cells11121959.
Cells. 2022.
PMID: 35741088
Free PMC article.